Nemorexant

Insomnia Data 2020: US Leads in Global Insomnia Clinical Trials, Germany Leads Major European Markets and Japan Has Top Spot in Asia

Retrieved on: 
Thursday, May 21, 2020
Branches of biology, G protein-coupled receptors, Protein families, Molecular neuroscience, Orexin receptor, Orexin, RTT, gamma-Aminobutyric acid, GABAA receptor, Insomnia, Hypocretin (orexin) receptor 1, Nemorexant

It is estimated that Asia had the largest number of prevalent cases in 2017 (675.7 million cases).

Key Points: 
  • It is estimated that Asia had the largest number of prevalent cases in 2017 (675.7 million cases).
  • The approved drugs in the insomnia space target GABA-A receptor, hypocretin/orexin receptor, chloride channel 2, chloride, melatonin receptor, histamine H1 receptor, and potassium channels.
  • Germany leads the major European markets, while Japan has the top spot in Asia.
  • Takeda leads the industry sponsors with the highest overall number of clinical trials for insomnia, followed by Merck & Co.